FGF21 and metabolic dysfunction-associated steatohepatitis: We found that butyrate could not only increased the expression of FFAR2, PPAR-γ, FGF21, and PGC-1α, which is consistent with previous studies, but may also alter the intestinal microbiota and barrier function to protect the liver from NASH.